Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01466374 · ClinicalTrials.gov registry record · Phase 2

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

A Phase 2 study of Crohn's Disease, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
121
Enrollment target
20
Study locations

NCT01466374 is a Phase 2 study of Crohn's Disease that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 121 participants, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01466374, a Phase 2 study of Crohn's Disease, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
121 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether BMS-936557 is effective for the treatment of moderate to severely active Crohn's Disease in patients who have had insufficient response and/or intolerance to conventional therapy for Crohn's Disease.

Conditions Studied

Crohn's Disease

Interventions

  • DRUG Placebo
  • DRUG BMS-936557 (Anti-IP-10 Antibody)

Study Locations (20)

Other

  • Local Institution - Brussels
  • Local Institution - Leuven
  • Local Institution - Amiens
  • Local Institution - Clichy
  • Local Institution - Nice
  • Local Institution - Pessac
  • Local Institution - Rouen
  • Local Institution - Vandœuvre-lès-Nancy
  • Local Institution - Budapest
  • Local Institution - Budapest

New York

  • Nyu Langone Long Island Clinical Research Associates - Great Neck
  • Mount Sinai School Of Medicine - New York

California

  • Southern California Medical Gastroenterology Group - Santa Monica

Florida

  • Shafran Gasteroenterology Center - Winter Park

Louisiana

  • Gastroenterology Research Of New Orleans - Hammond

Maryland

  • Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr - Chevy Chase

Missouri

  • Midwest Center For Clinical Research - Lees Summit

North Carolina

  • University Of North Carolina At Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 121 participants
Start Date 2011-12
Est. Completion 2014-12
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01466374

The ClinicalTrials.gov registry entry for NCT01466374 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (95% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01466374 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, New York, California.

Frequently Asked Questions

What is clinical trial NCT01466374 about?

NCT01466374 is a clinical study titled "Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease". The purpose of this study is to determine whether BMS-936557 is effective for the treatment of moderate to severely active Crohn's Disease in patients who have had insufficient response and/or intolerance to conventional therapy for Crohn's Disease.

What is the current status of trial NCT01466374?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2011-12. Estimated completion is 2014-12.

What conditions does trial NCT01466374 study?

This clinical trial studies the following conditions: Crohn's Disease.

What interventions are being tested in trial NCT01466374?

The interventions under investigation include: Placebo (DRUG), BMS-936557 (Anti-IP-10 Antibody) (DRUG).

Who is sponsoring clinical trial NCT01466374?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01466374 being conducted?

This trial has 20 study locations across California, Florida, Louisiana, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Crohn's Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.